Relmada Therapeutics financials
$3.73−1.58%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$15.0M | -$19.5M | -$20.3M | -$10.3M | -$10.2M | -$18.2M | -$19.1M | -$23.0M | -$18.8M | -$23.0M | -$26.8M | -$22.7M |
| Net income | -$12.9M | -$19.1M | -$19.9M | -$10.1M | -$9.9M | -$17.6M | -$18.7M | -$21.7M | -$17.8M | -$21.8M | -$25.2M | -$22.0M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.11 | $-0.22 | $-0.33 | $-0.30 | $-0.30 | $-0.58 | $-0.62 | $-0.72 | $-0.59 | $-0.72 | $-0.84 | $-0.73 |
| EBITDA | -$15.0M | -$19.5M | -$20.3M | -$10.3M | -$10.2M | -$18.2M | -$19.1M | -$23.0M | -$18.8M | -$23.0M | -$26.8M | -$22.7M |
| Operating cash flow | -$9.6M | -$15.1M | -$14.6M | -$6.7M | -$6.4M | -$18.1M | -$8.8M | -$16.7M | -$13.3M | -$13.0M | -$10.2M | -$11.6M |
| Free cash flow | -$9.6M | -$15.1M | -$14.6M | -$6.7M | -$6.4M | -$18.1M | -$8.8M | -$16.7M | -$13.3M | -$13.0M | -$10.2M | -$11.6M |
| Diluted shares | 112.4M | 86.6M | 61.1M | 33.2M | 33.2M | 30.4M | 30.2M | 30.2M | 30.2M | 30.1M | 30.1M | 30.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.3M | $9.8M | $3.5M | $1.4M | $1.4M | $1.1M |
| Short-term investments | $206.4M | $224.2M | $89.5M | $12.5M | $19.3M | $25.9M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $219.1M | $235.4M | $94.0M | $14.9M | $21.1M | $27.7M |
| Total liabilities | $12.5M | $16.6M | $7.5M | $5.4M | $5.2M | $5.2M |
| Shareholders' equity | $206.6M | $218.7M | $86.5M | $9.5M | $15.9M | $22.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology